Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Open in Screener

PTGX

Protagonist Therapeutics Inc

May 03 • 04:00PM ET

26.09

Dollar change +0.55
Percentage change 2.15	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: VTI IWM VXF IBB IWO SCHA VTWO IWN LABU VHT

Index	RUT	P/E	-	EPS (ttm)	-1.48	Insider Own	5.96%	Shs Outstand	57.71M	Perf Week	3.74%
Market Cap	1.52B	Forward P/E	-	EPS next Y	-0.81	Insider Trans	-4.80%	Shs Float	54.80M	Perf Month	-5.64%
Income	-78.95M	PEG	-	EPS next Q	1.19	Inst Own	98.56%	Short Float	6.43%	Perf Quarter	-1.51%
Sales	60.00M	P/S	25.34	EPS this Y	194.96%	Inst Trans	-9.31%	Short Ratio	6.08	Perf Half Y	72.67%
Book/sh	5.83	P/B	4.47	EPS next Y	-161.03%	ROA	-26.05%	Short Interest	3.52M	Perf Year	6.71%
Cash/sh	5.86	P/C	4.45	EPS next 5Y	-	ROE	-28.59%	52W Range	13.72 - 33.34	Perf YTD	13.78%
Dividend Est.	-	P/FCF	-	EPS past 5Y	4.38%	ROI	-23.45%	52W High	-21.75%	Beta	2.12
Dividend TTM	-	Quick Ratio	16.71	Sales past 5Y	2462.45%	Gross Margin	94.48%	52W Low	90.16%	ATR (14)	1.07
Dividend Ex-Date	-	Current Ratio	16.71	EPS Y/Y TTM	43.46%	Oper. Margin	-156.09%	RSI (14)	46.73	Volatility	3.47% 3.86%
Employees	112	Debt/Eq	0.00	Sales Y/Y TTM	125.73%	Profit Margin	-131.59%	Recom	1.17	Target Price	43.00
Option/Short	Yes / Yes	LT Debt/Eq	0.00	EPS Q/Q	163.72%	Payout	-	Rel Volume	0.61	Prev Close	25.54
Sales Surprise	0.00%	EPS Surprise	720.90%	Sales Q/Q	-	Earnings	Feb 28 BMO	Avg Volume	579.07K	Price	26.09
SMA20	-1.10%	SMA50	-7.24%	SMA200	19.13%	Trades		Volume	355,687	Change	2.15%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-30-23	Initiated	CapitalOne	Overweight	$32
May-25-23	Resumed	Jefferies	Buy	$30 → $40
Aug-25-22	Initiated	JMP Securities	Mkt Outperform	$21
Feb-11-22	Initiated	BTIG Research	Buy	$55
Oct-12-21	Upgrade	JP Morgan	Neutral → Overweight	$49 → $55
Oct-11-21	Upgrade	Northland Capital	Market Perform → Outperform	$40
Sep-20-21	Downgrade	JP Morgan	Overweight → Neutral	$60 → $49
May-24-21	Initiated	Northland Capital	Outperform	$42
May-24-21	Initiated	JMP Securities	Mkt Outperform	$48
Jan-06-21	Initiated	JP Morgan	Overweight
Dec-16-20	Initiated	Piper Sandler	Overweight	$53
Sep-18-20	Reiterated	H.C. Wainwright	Buy	$28 → $33
Jul-15-20	Initiated	Jefferies	Buy	$27
May-18-20	Reiterated	H.C. Wainwright	Buy	$23 → $28
Jul-08-19	Initiated	H.C. Wainwright	Buy	$23
May-09-19	Upgrade	Stifel	Hold → Buy	$11 → $17
Dec-06-18	Initiated	Nomura	Buy	$13
Jan-29-18	Initiated	Stifel	Buy	$32
Jul-21-17	Initiated	BTIG Research	Buy	$36

Show Previous Ratings

Apr-16-24 09:00AM	Turnstone Biologics Appoints William Waddill to its Board of Directors (GlobeNewswire)
Apr-05-24 12:00PM	All You Need to Know About Protagonist Therapeutics (PTGX) Rating Upgrade to Buy (Zacks)
Apr-03-24 01:52AM	Protagonist Therapeutics Inc CEO Sells 25,000 Shares (GuruFocus.com)
Mar-26-24 07:00AM	Protagonist Therapeutics Provides Update on VERIFY Patient Enrollment and Timing of Top-line Data (ACCESSWIRE)
Mar-18-24 09:55AM	Wall Street Analysts Think Protagonist Therapeutics (PTGX) Could Surge 48.38%: Read This Before Placing a Bet (Zacks)
07:00AM	Loading…
07:00AM	Protagonist Therapeutics Announces Closing of Worldwide Rusfertide License and Collaboration Agreement with Takeda (ACCESSWIRE)
Mar-11-24 07:00AM	Late-Breaking Presentation at American Academy of Dermatology 2024 Annual Meeting Shows that JNJ-2113, the First and Only Investigational Targeted Oral Peptide, Maintained Skin Clearance in Moderate-To-Severe Plaque Psoriasis Through One Year (ACCESSWIRE)
Mar-06-24 04:05PM	Protagonist Therapeutics to Participate in Upcoming Investor Conferences (ACCESSWIRE)
Mar-01-24 12:20PM	Earnings Estimates Moving Higher for Protagonist Therapeutics (PTGX): Time to Buy? (Zacks) +5.83%
12:00PM	Protagonist Therapeutics (PTGX) Upgraded to Buy: What Does It Mean for the Stock? (Zacks)
12:00PM	Are You Looking for a Top Momentum Pick? Why Protagonist Therapeutics (PTGX) is a Great Choice (Zacks)
09:55AM	Wall Street Analysts Believe Protagonist Therapeutics (PTGX) Could Rally 37.16%: Here's is How to Trade (Zacks)
08:50AM	Recent Price Trend in Protagonist Therapeutics (PTGX) is Your Friend, Here's Why (Zacks)
Feb-27-24 04:38PM	Protagonist Therapeutics: Q4 Earnings Snapshot (Associated Press Finance)
04:05PM	Protagonist Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update (ACCESSWIRE)
05:00PM	Loading…
Feb-21-24 05:00PM	New England Journal of Medicine Publishes Results of Positive Randomized Phase 2 REVIVE Trial of Rusfertide in Treatment of Polycythemia Vera (ACCESSWIRE)
Feb-20-24 04:05PM	Protagonist Therapeutics Reports Granting of Inducement Awards (ACCESSWIRE)
Feb-15-24 03:13AM	Steven Cohen Adjusts Position in Protagonist Therapeutics Inc (GuruFocus.com)
Feb-07-24 05:00PM	New England Journal of Medicine Publishes Efficacy and Safety Data of Targeted Oral Peptide JNJ-2113 in a Phase 2b Moderate-To-Severe Plaque Psoriasis Study (ACCESSWIRE)
Feb-02-24 01:03PM	Protagonist (PTGX) Up 14% on Licensing Deal With Takeda (Zacks) -7.12%
Feb-01-24 06:35AM	Takeda pays $300M to license Protagonist drug for blood disorder (BioPharma Dive) +14.03%
Jan-31-24 04:05PM	Takeda and Protagonist Therapeutics, Inc. Enter into Worldwide License and Collaboration Agreement for Rusfertide, a Late-Stage Rare Hematology Asset (ACCESSWIRE)
Jan-29-24 07:30AM	Protagonist Therapeutics to Participate in Fireside Chat at Guggenheim Healthcare Talks 2024 (ACCESSWIRE) +6.78%
Jan-12-24 03:02AM	Insider Suneel Gupta Sells 5,000 Shares of Protagonist Therapeutics Inc (PTGX) (GuruFocus.com) +6.06%
Jan-03-24 07:30AM	Protagonist Therapeutics to Participate in the 42nd Annual J.P. Morgan Healthcare Conference (ACCESSWIRE)
Dec-16-23 11:01AM	Insider Sell Alert: CEO PATEL DINESH V PH D Sells 75,000 Shares of Protagonist Therapeutics Inc ... (GuruFocus.com)
Dec-13-23 07:30AM	Protagonist Earns $10 Million Payment for Achievement of Clinical Milestone in Phase 2b ANTHEM-UC Study of JNJ-2113 in Adults with Moderately to Severely Active Ulcerative Colitis (ACCESSWIRE)
Dec-12-23 09:04AM	Protagonist Reports 2-Year Follow Up Data from Rusfertide REVIVE Study at the ASH Annual Meeting Showing Durable Efficacy and No New Safety Signals (ACCESSWIRE)
Nov-27-23 09:00AM	Protagonist Announces Two New Phase 3 ICONIC Studies in Psoriasis Evaluating JNJ-2113 in Head-to-Head Comparisons with Deucravacitinib (ACCESSWIRE)
Nov-16-23 04:05PM	Protagonist Therapeutics Reports Granting of Inducement Awards (ACCESSWIRE)
05:50AM	Loading…
05:50AM	Looking for Stocks to Buy? Here Are the Companies Johnson & Johnson Is Betting the Most On (Motley Fool)
Nov-09-23 03:55PM	Protagonist Therapeutics Ranked in the Top 3% of Fastest-Growing Companies in North America on the 2023 Deloitte Technology Fast 500(TM) (ACCESSWIRE) -5.82%
09:55AM	Does Protagonist Therapeutics (PTGX) Have the Potential to Rally 141.08% as Wall Street Analysts Expect? (Zacks)
Nov-04-23 05:42AM	Protagonist Therapeutics Inc (PTGX) Reports Q3 2023 Financial Results (GuruFocus.com)
Nov-02-23 06:24PM	Protagonist Therapeutics: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	Protagonist Reports Third Quarter 2023 Financial Results and Provides Corporate Update (ACCESSWIRE)
09:05AM	Protagonist Therapeutics Announces Abstracts Selected for Oral and Poster Presentations at the American Society of Hematology 2023 Annual Meeting (ACCESSWIRE)
Nov-01-23 04:05PM	Protagonist Announces Achievement of $50M Milestone Event After Third Patient is Dosed in Phase 3 Study of JNJ-2113 in Moderate-to-Severe Psoriasis (ACCESSWIRE)
07:30AM	Protagonist Therapeutics to Participate in Upcoming Investor Conferences (ACCESSWIRE)
Oct-30-23 04:05PM	Protagonist Therapeutics Announces Appointment of Daniel Swisher to Its Board of Directors (ACCESSWIRE)
Oct-09-23 07:00AM	Protagonist Announces Advancement of JNJ-2113 Across Multiple Indications (ACCESSWIRE)
Oct-03-23 04:05PM	Protagonist Therapeutics Reports Granting of Inducement Award (ACCESSWIRE)
Sep-05-23 07:30AM	Protagonist Therapeutics to Present at Upcoming Investor Conferences (ACCESSWIRE)
Aug-16-23 04:05PM	Protagonist Therapeutics Reports Granting of Inducement Award (ACCESSWIRE)
Aug-09-23 07:00AM	Protagonist Receives $34 Million from Warrant Exercises (ACCESSWIRE)
Aug-03-23 04:48PM	Protagonist Therapeutics: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	Protagonist Reports Second Quarter 2023 Financial Results and Provides Corporate Update (ACCESSWIRE)
Jul-18-23 04:05PM	Protagonist Therapeutics Reports Granting of Inducement Award (ACCESSWIRE)
Jul-05-23 09:33AM	Protagonist Therapeutics-Janssen Partnered Psoriasis Candidate Fall Short Of Rival Treatment (Benzinga)
Jul-04-23 03:30AM	Protagonist Therapeutics Announces Positive Topline Results with JNJ-2113, the First and Only Oral IL-23 Receptor Antagonist Peptide in Development for Moderate-to-Severe Plaque Psoriasis (ACCESSWIRE)
Jun-30-23 08:50AM	Protagonist Therapeutics (PTGX) Is a Great Choice for 'Trend' Investors, Here's Why (Zacks)
Jun-15-23 09:55AM	Wall Street Analysts Predict a 25.35% Upside in Protagonist Therapeutics (PTGX): Here's What You Should Know (Zacks)
Jun-13-23 08:50AM	Here's Why Momentum in Protagonist Therapeutics (PTGX) Should Keep going (Zacks)
Jun-09-23 08:05AM	Clinical Response and Durability of Response of Rusfertide (PTG-300) in Polycythemia Vera Featured Today at EHA Press Briefing; Protagonist Therapeutics Plans a Follow-on Two-Year Extension Study to Enable Further Evaluation of the Long-Term Effects of Rusfertide in PV (ACCESSWIRE)
Jun-06-23 07:30AM	Protagonist Therapeutics Announces Acceptance of Late-Breaking Abstract for Oral Presentation at 2023 European Hematology Association (EHA) Congress (ACCESSWIRE)
Jun-01-23 04:01PM	Protagonist Therapeutics to Participate in the 2023 Jefferies Healthcare Conference (ACCESSWIRE) +5.45%
May-26-23 09:55AM	How Much Upside is Left in Protagonist Therapeutics (PTGX)? Wall Street Analysts Think 38.01% (Zacks)
May-12-23 03:14PM	Promising Phase 1 Results: Protagonist Therapeutics and Janssen Biotech Unlock New Potential in Colitis and Inflammation Treatment (Benzinga)
07:00AM	Protagonist Reports Positive Results from Phase 1 and Pre-clinical Studies of Oral Interleukin-23 Receptor Antagonist JNJ-2113 (PR Newswire)
May-11-23 04:05PM	Protagonist Therapeutics to Participate in the JMP Securities Life Sciences Conference (PR Newswire)
10:17AM	Protagonist Therapeutics Announces Presentations at the 2023 Annual Congress of the European Hematology Association (PR Newswire)
May-05-23 04:03PM	Protagonist, A Top 1% Biotech, Briefly Breaks Out On Psoriasis Enthusiasm (Investor's Business Daily) +5.13%
May-04-23 05:02PM	Protagonist Therapeutics: Q1 Earnings Snapshot (AP Finance)
04:05PM	Protagonist Reports First Quarter 2023 Financial Results and Provides Corporate Update (PR Newswire)
Apr-20-23 09:51PM	Why Shares of Protagonist Therapeutics Rose This Week (Motley Fool)
Apr-17-23 06:35AM	Protagonist Therapeutics, Inc.'s (NASDAQ:PTGX) Business Is Yet to Catch Up With Its Share Price (Simply Wall St.) +10.03%
Apr-04-23 10:45PM	Protagonist Therapeutics Announces Pricing of $100 Million Public Offering of Shares of Common Stock (ACCESSWIRE) -5.57%
04:11PM	Protagonist Therapeutics Announces Proposed Underwritten Public Offering of Common Stock (ACCESSWIRE)
Mar-21-23 03:49AM	Strength Seen in Nurix Therapeutics, Inc. (NRIX): Can Its 5.7% Jump Turn into More Strength? (Zacks)
Mar-20-23 06:08AM	Analysts Just Made A Major Revision To Their Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Revenue Forecasts (Simply Wall St.)
Mar-17-23 06:06AM	Protagonist Therapeutics (NASDAQ:PTGX) Is In A Good Position To Deliver On Growth Plans (Simply Wall St.)
Mar-15-23 04:01PM	Protagonist Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update (ACCESSWIRE)
01:39PM	Protagonist Therapeutics Touts Positive Data From Bone Marrow Disorder Study (Benzinga)
07:30AM	Protagonist Therapeutics Announces Highly Statistically Significant Results from the Randomized Withdrawal Portion of the REVIVE Study of Rusfertide in Polycythemia Vera (ACCESSWIRE)
Mar-09-23 11:14AM	Biotech Stock Roundup: PTGX Gains on Study Data, BMRN Faces Setback & More (Zacks)
Mar-08-23 12:19PM	Protagonist (PTGX) Up on Positive Results From FRONTIER Study (Zacks)
10:02AM	Protagonist Therapeutics (PTGX) Soars 51.9%: Is Further Upside Left in the Stock? (Zacks)
Mar-07-23 11:54AM	Why Protagonist Therapeutics Shares Are Trading Higher Today (Benzinga) +51.91%
08:00AM	Protagonist Therapeutics Announces Positive Topline Results for Phase 2b FRONTIER 1 Clinical Trial of Oral IL-23 Receptor Antagonist JNJ-2113 (PN-235) in Psoriasis (PR Newswire)
Jan-25-23 03:24AM	Protagonist Therapeutics (PTGX) Moves 10.7% Higher: Will This Strength Last? (Zacks)
Jan-14-23 07:14AM	Are Investors Undervaluing Protagonist Therapeutics, Inc. (NASDAQ:PTGX) By 50%? (Simply Wall St.)
Dec-21-22 04:05PM	Protagonist Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference (PR Newswire) +5.05%
Dec-05-22 09:55AM	Can Protagonist Therapeutics (PTGX) Climb 323% to Reach the Level Wall Street Analysts Expect? (Zacks)
Dec-01-22 07:05AM	Protagonist Therapeutics to Participate in the JMP Securities Hematology and Oncology Summit (PR Newswire)
Nov-16-22 04:05PM	Protagonist Therapeutics Reports Granting of Inducement Award (PR Newswire)
Nov-11-22 09:55AM	How Much Upside is Left in Protagonist Therapeutics (PTGX)? Wall Street Analysts Think 337% (Zacks)
05:11AM	Protagonist Therapeutics Third Quarter 2022 Earnings: US$0.64 loss per share (vs US$0.70 loss in 3Q 2021) (Simply Wall St.)
Nov-08-22 04:05PM	Protagonist Reports Third Quarter 2022 Financial Results and Provides Corporate Update (PR Newswire)
Nov-03-22 09:16AM	Protagonist Therapeutics Announces Poster Presentations at the American Society of Hematology 2022 Annual Meeting (PR Newswire)
Oct-12-22 06:10AM	Investors in Protagonist Therapeutics (NASDAQ:PTGX) have unfortunately lost 74% over the last year (Simply Wall St.)
Oct-05-22 09:55AM	Does Protagonist Therapeutics (PTGX) Have the Potential to Rally 322% as Wall Street Analysts Expect? (Zacks)
Oct-02-22 07:39AM	Stocks Are Looking Increasingly Cheap, Says J.P. Morgan; Here Are 2 Names to Consider (TipRanks)
Sep-23-22 12:00PM	Protagonist Therapeutics (PTGX) Upgraded to Buy: What Does It Mean for the Stock? (Zacks)
Sep-20-22 05:40PM	Protagonist Therapeutics Reports Granting of Inducement Award (PR Newswire)
Aug-10-22 09:55AM	How Much Upside is Left in Protagonist Therapeutics (PTGX)? Wall Street Analysts Think 302% (Zacks)
Aug-04-22 07:15PM	Protagonist Therapeutics (PTGX) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
04:05PM	Protagonist Reports Second Quarter 2022 Financial Results and Provides Corporate Update (PR Newswire)
Jul-19-22 07:00AM	Protagonist Therapeutics Reports Granting of Inducement Award (PR Newswire) +7.22%
Jul-18-22 06:11AM	Novavax (NVAX) Soars 5.4%: Is Further Upside Left in the Stock? (Zacks)
Jul-17-22 09:11AM	We're Hopeful That Protagonist Therapeutics (NASDAQ:PTGX) Will Use Its Cash Wisely (Simply Wall St.)

Protagonist Therapeutics, Inc. a clinical-stage biopharmaceutical company, which engages in discovering and developing peptide-based therapeutic drugs to address unmet medical needs. Its product pipeline includes PTG-300, PTG-200, and PN-943. The company was founded by Mark L. Smythe on August 22, 2006 and is headquartered in Newark, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Ali Asif	Chief Financial Officer	Apr 18 '24	Sale	25.11	1,234	30,986	37,163	Apr 19 08:05 PM
PATEL DINESH V PH D	President and CEO	Apr 01 '24	Sale	28.31	25,000	707,750	549,590	Apr 02 08:29 PM
SELICK HAROLD E	Director	Mar 07 '24	Option Exercise	1.89	6,490	12,266	27,996	Mar 11 08:00 PM
Ali Asif	Chief Financial Officer	Mar 01 '24	Option Exercise	12.17	12,000	146,040	52,645	Mar 01 08:45 PM
Waddill William D.	Director	Mar 01 '24	Option Exercise	6.09	12,975	79,018	24,975	Mar 01 08:45 PM
PATEL DINESH V PH D	President and CEO	Mar 01 '24	Sale	31.62	30,000	948,600	574,590	Mar 01 08:46 PM
Ali Asif	Chief Financial Officer	Mar 01 '24	Sale	32.24	14,248	459,318	38,397	Mar 01 08:45 PM
Waddill William D.	Director	Mar 01 '24	Sale	31.34	12,975	406,636	12,000	Mar 01 08:45 PM
Ali Asif	Chief Financial Officer	Feb 29 '24	Sale	30.69	9,939	305,048	40,645	Mar 01 08:45 PM
Gupta Suneel	Chief Development Officer	Jan 09 '24	Option Exercise	7.38	5,000	36,900	192,567	Jan 11 08:00 PM
Gupta Suneel	Chief Development Officer	Jan 09 '24	Sale	25.00	5,000	125,000	187,567	Jan 11 08:00 PM
PATEL DINESH V PH D	President and CEO	Dec 13 '23	Sale	20.08	75,000	1,506,000	534,347	Dec 15 04:30 PM
MOLINA ARTURO MD	Chief Medical Officer	Nov 15 '23	Sale	16.24	1,848	30,012	22,527	Jan 04 08:09 PM
Gupta Suneel	Chief Development Officer	Oct 19 '23	Option Exercise	7.38	20,000	147,600	168,317	Oct 23 04:31 PM
PATEL DINESH V PH D	President and CEO	Oct 18 '23	Option Exercise	4.21	6,000	25,260	609,347	Oct 19 04:55 PM

Open in Screener

ARWR

Arrowhead Pharmaceuticals Inc.

May 03 • 04:00PM ET

24.44

Dollar change +0.31
Percentage change 1.28	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

ARWR Arrowhead Pharmaceuticals Inc. daily Stock Chart

Held by: VTI IJH VB IWM VXF VBK IWO IJK IBB SCHA

Index	RUT	P/E	-	EPS (ttm)	-2.77	Insider Own	4.95%	Shs Outstand	123.90M	Perf Week	10.49%
Market Cap	3.03B	Forward P/E	-	EPS next Y	-2.50	Insider Trans	-4.08%	Shs Float	117.77M	Perf Month	-6.40%
Income	-296.81M	PEG	-	EPS next Q	-0.47	Inst Own	64.71%	Short Float	7.53%	Perf Quarter	-23.53%
Sales	181.74M	P/S	16.66	EPS this Y	-37.39%	Inst Trans	-1.58%	Short Ratio	6.93	Perf Half Y	-5.23%
Book/sh	1.49	P/B	16.38	EPS next Y	5.40%	ROA	-39.11%	Short Interest	8.87M	Perf Year	-39.20%
Cash/sh	1.78	P/C	13.75	EPS next 5Y	7.33%	ROE	-110.45%	52W Range	20.67 - 42.48	Perf YTD	-20.13%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-24.19%	ROI	-54.04%	52W High	-42.47%	Beta	0.95
Dividend TTM	-	Quick Ratio	3.73	Sales past 5Y	205.96%	Gross Margin	92.26%	52W Low	18.24%	ATR (14)	1.24
Dividend Ex-Date	-	Current Ratio	3.73	EPS Y/Y TTM	-89.69%	Oper. Margin	-164.75%	RSI (14)	48.48	Volatility	5.05% 4.61%
Employees	525	Debt/Eq	2.45	Sales Y/Y TTM	-34.71%	Profit Margin	-163.32%	Recom	1.53	Target Price	53.66
Option/Short	Yes / Yes	LT Debt/Eq	2.42	EPS Q/Q	-217.40%	Payout	-	Rel Volume	0.49	Prev Close	24.13
Sales Surprise	-89.52%	EPS Surprise	-54.81%	Sales Q/Q	-94.32%	Earnings	May 09 AMC	Avg Volume	1.28M	Price	24.44
SMA20	2.54%	SMA50	-11.15%	SMA200	-15.12%	Trades		Volume	630,825	Change	1.28%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-04-23	Initiated	BofA Securities	Buy	$29
Sep-19-23	Initiated	Citigroup	Neutral	$33
Jul-21-23	Initiated	TD Cowen	Outperform
May-12-23	Downgrade	SVB Securities	Outperform → Market Perform	$40
Apr-26-23	Initiated	SMBC Nikko	Outperform	$80
Apr-12-23	Upgrade	SVB Securities	Market Perform → Outperform	$21 → $35
Mar-21-23	Initiated	Bernstein	Mkt Perform	$27
Sep-09-22	Initiated	Morgan Stanley	Equal-Weight	$41
May-11-22	Upgrade	Robert W. Baird	Neutral → Outperform	$71 → $60
Jan-19-22	Resumed	Goldman	Buy	$90 → $85
Aug-06-21	Reiterated	Chardan Capital Markets	Buy	$97 → $94
Jun-04-21	Resumed	Robert W. Baird	Neutral	$85
Feb-05-21	Reiterated	H.C. Wainwright	Buy	$90 → $95
Dec-21-20	Downgrade	Robert W. Baird	Outperform → Neutral	$75
Dec-16-20	Initiated	UBS	Buy	$95
Nov-19-20	Initiated	Citigroup	Buy	$90
May-13-20	Initiated	RBC Capital Mkts	Outperform	$62
May-08-20	Upgrade	Oppenheimer	Perform → Outperform	$58
Apr-15-20	Upgrade	Cantor Fitzgerald	Neutral → Overweight	$55 → $60
Mar-24-20	Upgrade	SVB Leerink	Underperform → Mkt Perform	$29

Show Previous Ratings

May-03-24 07:26AM	Arrowhead Nets $50 Milestone Payment from Royalty Pharma After Completion of Enrollment in Trial of Cardiovascular Drug (MT Newswires)
May-02-24 04:01PM	Arrowhead Pharmaceuticals Earns $50 Million Milestone from Royalty Pharma (Business Wire)
Apr-29-24 07:30AM	Arrowhead Pharmaceuticals to Participate in Upcoming May 2024 Conferences (Business Wire)
Apr-26-24 07:30AM	Arrowhead Pharmaceuticals to Host 2024 Summer Series of R&D Webinars (Business Wire)
Apr-24-24 04:01PM	Arrowhead Pharmaceuticals to Webcast Fiscal 2024 Second Quarter Results (Business Wire)
07:30AM	Loading…
07:30AM	Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-CFB for Treatment of Complement Mediated Kidney Disease (Business Wire)
Apr-16-24 09:00AM	Turnstone Biologics Appoints William Waddill to its Board of Directors (GlobeNewswire)
Apr-07-24 09:00AM	Arrowhead Pharmaceuticals Announces New Phase 2 Data of Plozasiran Published in JAMA Cardiology and Presented at American College of Cardiology 73rd Annual Scientific Session & Expo (Business Wire)
Apr-04-24 01:27AM	Insider Sell: Chief Discovery/Trans Medicine James Hamilton Sells 6,000 Shares of Arrowhead ... (GuruFocus.com)
Apr-01-24 04:30PM	Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) (Business Wire)
Mar-25-24 08:00AM	Arrowhead Pharmaceuticals Initiates Expanded Access Program for Plozasiran and Announces Upcoming Presentation of Clinical Data (Business Wire)
Mar-11-24 06:53PM	The 3 Most Undervalued Russell 2000 Stocks to Buy in March 2024 (InvestorPlace) -12.11%
Mar-08-24 11:29PM	Arrowhead Pharmaceuticals Inc CFO Kenneth Myszkowski Sells 40,000 Shares (GuruFocus.com)
07:30AM	Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-DM1 for Treatment of Type 1 Myotonic Dystrophy (Business Wire)
Mar-04-24 07:30AM	Arrowhead Pharmaceuticals to Participate in Upcoming March 2024 Conferences (Business Wire)
10:42AM	Loading…
Feb-07-24 10:42AM	Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Q1 2024 Earnings Call Transcript (Insider Monkey)
10:02AM	Q1 2024 Arrowhead Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
Feb-06-24 04:32PM	Arrowhead Research: Fiscal Q1 Earnings Snapshot (Associated Press Finance)
04:32PM	Arrowhead Pharmaceuticals Inc Reports Fiscal Q1 2024 Results with Strategic Focus on ... (GuruFocus.com)
04:01PM	Arrowhead Pharmaceuticals Reports Fiscal 2024 First Quarter Results (Business Wire)
Jan-22-24 04:01PM	Arrowhead Pharmaceuticals to Webcast Fiscal 2024 First Quarter Results (Business Wire)
Jan-18-24 05:37AM	Bank of America Says These 3 Healthcare Stocks Have up to ~160% Upside Potential (TipRanks)
Jan-09-24 03:02AM	Arrowhead Pharmaceuticals Inc CFO Kenneth Myszkowski Sells 16,104 Shares (GuruFocus.com)
Jan-06-24 01:01PM	Arrowhead Pharmaceuticals Inc Insider Sells Shares (GuruFocus.com)
Jan-05-24 05:00PM	Arrowhead Pharmaceuticals Closes Underwritten Offering with Gross Proceeds of $450.0 Million (Business Wire)
11:02AM	Arrowhead Pharmaceuticals Inc CEO Christopher Anzalone Sells 9,952 Shares (GuruFocus.com)
Jan-03-24 07:00AM	Arrowhead Pharmaceuticals Announces Pricing of $450.0 Million Underwritten Offering of Common Stock (Business Wire)
Dec-29-23 04:01PM	Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) (Business Wire)
Dec-24-23 09:01AM	Arrowhead Pharmaceuticals Inc CEO Christopher Anzalone Sells 12,000 Shares (GuruFocus.com)
Dec-21-23 07:30AM	Arrowhead Pharmaceuticals Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-CFB for Complement Mediated Kidney Disease (Business Wire)
07:30AM	Loading…
Dec-20-23 07:30AM	Arrowhead Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference (Business Wire) -7.23%
Dec-01-23 09:32AM	Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Q4 2023 Earnings Call Transcript (Insider Monkey) +9.29%
Nov-30-23 12:22PM	Q4 2023 Arrowhead Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents) -26.85%
Nov-29-23 04:51PM	Arrowhead Pharmaceuticals Inc Reports Fiscal 2023 Year-End Results (GuruFocus.com)
04:01PM	Arrowhead Pharmaceuticals Reports Fiscal 2023 Year End Results (Business Wire)
Nov-28-23 07:30AM	Arrowhead Pharmaceuticals Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-DM1 for Type 1 Myotonic Dystrophy (Business Wire)
Nov-22-23 09:46PM	Insider Sell Alert: Chief Medical Officer Martin San Sells 19,700 Shares of Arrowhead ... (GuruFocus.com)
Nov-21-23 04:01PM	Arrowhead Pharmaceuticals to Participate in Piper Sandler 35th Annual Healthcare Conference (Business Wire)
Nov-16-23 07:30AM	Arrowhead Pharmaceuticals to Webcast Fiscal 2023 Year End Results (Business Wire)
Nov-13-23 09:30AM	Arrowhead Presents New Phase 2 Data on Plozasiran and Zodasiran at AHA 2023 (Business Wire)
Nov-06-23 07:30AM	Arrowhead Pharmaceuticals to Participate in Jefferies London Healthcare Conference (Business Wire)
Nov-02-23 07:30AM	Arrowhead Pharmaceuticals to Present New Phase 2 Clinical Data on Cardiometabolic Pipeline at AHA 2023 (Business Wire)
Oct-31-23 08:30AM	UPDATE 1-GSK to pay $1 bln for exclusive license to J&J's hepatitis B therapy (Reuters) +5.90%
07:46AM	GSK signs $1 bln deal for exclusive license to J&J's hepatitis B therapy (Reuters)
Oct-28-23 05:02AM	Insider Sell: CEO Christopher Anzalone Sells 24,338 Shares of Arrowhead Pharmaceuticals Inc (GuruFocus.com)
Oct-03-23 04:01PM	Arrowhead Pharmaceuticals to Participate in Upcoming October 2023 Conferences (Business Wire)
Sep-27-23 04:30PM	Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) (Business Wire)
Sep-21-23 05:01AM	Insider Sell: CEO Christopher Anzalone Sells 57,755 Shares of Arrowhead Pharmaceuticals Inc (GuruFocus.com)
Sep-11-23 07:30AM	Arrowhead Presents Data on Pulmonary Pipeline at ERS 2023 (Business Wire)
Sep-09-23 03:59PM	10 Biotech Stocks with Biggest Upside (Insider Monkey)
Sep-07-23 07:34PM	Is Arrowhead Pharmaceuticals (ARWR) Too Good to Be True? A Comprehensive Analysis of a ... (GuruFocus.com)
Sep-01-23 07:30AM	Arrowhead Pharmaceuticals to Participate in Upcoming September 2023 Conferences (Business Wire)
Aug-13-23 08:32AM	Swelling losses haven't held back gains for Arrowhead Pharmaceuticals (NASDAQ:ARWR) shareholders since they're up 99% over 5 years (Simply Wall St.)
Aug-10-23 08:10AM	ARWR: Enrollment Complete in PALISADE Phase 3 Trial of ARO-APOC3 in FCS... (Zacks)
Aug-08-23 09:42AM	Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Q3 2023 Earnings Call Transcript (Insider Monkey) -10.78%
09:13AM	Q3 2023 Arrowhead Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
06:20AM	15 Worst Performing Biotech Stocks in 2023 (Insider Monkey)
Aug-07-23 04:16PM	Arrowhead Research: Fiscal Q3 Earnings Snapshot (AP Finance)
04:01PM	Arrowhead Pharmaceuticals Reports Fiscal 2023 Third Quarter Results (Business Wire)
Jul-24-23 04:00PM	Arrowhead Pharmaceuticals to Webcast Fiscal 2023 Third Quarter Results (Business Wire)
Jul-17-23 07:30AM	Arrowhead Pharmaceuticals Files for Regulatory Clearance to Initiate a Phase 1/2 Study of ARO-DUX4 for Facioscapulohumeral Muscular Dystrophy (Business Wire)
Jul-06-23 04:30PM	Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) (Business Wire)
Jun-30-23 06:52AM	Daily Vickers Top Buyers & Sellers for 06/30/2023 (Argus Research)
Jun-27-23 07:30AM	Arrowhead Pharmaceuticals Files for Regulatory Clearance to Initiate a Phase 1 Study of ARO-SOD1 (Business Wire)
Jun-24-23 08:15AM	Arrowhead Presents Updated Data from Phase 2 SEQUOIA Study of Investigational RNAi Therapy Fazirsiran in Patients with Alpha-1 Antitrypsin Deficiency Liver Disease (Business Wire)
Jun-21-23 08:00PM	ARWR: What does Argus have to say about ARWR? (Argus Research)
Jun-14-23 06:34PM	Goldman Sachs Lifts S&P 500 Price Target; Here Are 2 High-Upside Stocks to Play the Bounce (TipRanks)
Jun-06-23 07:30AM	Arrowhead Pharmaceuticals to Participate in Upcoming June 2023 Conferences (Business Wire)
Jun-01-23 04:07PM	Arrowhead CEO Christopher Anzalone Addresses This 'Really Important Event' In Lung Disease (Investor's Business Daily)
07:30AM	Arrowhead Hosts R&D Day Highlighting Its Pipeline of RNAi Therapeutics (Business Wire)
07:07AM	After a year of 4.1% returns, Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) share price drop last week may have less of an impact on institutional investors (Simply Wall St.)
May-23-23 07:30AM	Arrowhead Presents Interim Data from ARO-ANG3 Phase 2 GATEWAY Study in Patients with HoFH (Business Wire)
May-16-23 07:30AM	Arrowhead Pharmaceuticals Completes Enrollment of Phase 3 PALISADE Clinical Trial Evaluating ARO-APOC3 for Treatment of Familial Chylomicronemia Syndrome (Business Wire) -5.64%
May-15-23 04:00PM	Arrowhead Pharmaceuticals to Participate in Upcoming Conferences (Business Wire)
May-11-23 09:27AM	ARWR: Interim Data for Phase 1/2 Trial of ARO-RAGE Shows Potential for Pulmonary TRiM Platform (Zacks Small Cap Research)
May-10-23 06:25AM	Does Arrowhead Pharmaceuticals (ARWR) Have a Long Runway for Growth? (Insider Monkey)
May-04-23 06:24AM	Arrowhead Pharmaceuticals Second Quarter 2023 Earnings: Beats Expectations (Simply Wall St.)
May-02-23 04:17PM	Arrowhead Research: Fiscal Q2 Earnings Snapshot (AP Finance)
04:01PM	Arrowhead Pharmaceuticals Reports Fiscal 2023 Second Quarter Results (Business Wire)
Apr-26-23 08:00PM	ARWR: Rating decreased to a SELL (Argus Research) +5.78%
07:06AM	Biotech Stock Roundup: BIIB's Q1 Results, ARWR Up on Data, INCY & BLUE Offer Updates (Zacks)
Apr-25-23 01:19PM	Arrowhead Pharmaceuticals Reveals Data From Healthy Volunteers For Its Asthma Hopeful, Stock Soars (Benzinga) +11.86%
11:20AM	Why Shares of Arrowhead Pharmaceuticals Are Up Tuesday (Motley Fool)
07:30AM	Arrowhead Pharmaceuticals Proprietary Pulmonary TRiM Platform Achieves High Levels of Target Gene Knockdown and Long Duration of Effect (Business Wire)
Apr-18-23 07:30AM	Arrowhead Pharmaceuticals to Webcast Fiscal 2023 Second Quarter Results (Business Wire)
Apr-17-23 08:17AM	Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) Shares Climb 25% But Its Business Is Yet to Catch Up (Simply Wall St.)
Apr-16-23 05:21AM	Is Arrowhead Pharmaceuticals a Buy Now? (Motley Fool)
Apr-12-23 07:30AM	Arrowhead Pharmaceuticals to Host R&D Day on Pipeline of RNAi Therapeutics (Business Wire) +8.88%
Apr-04-23 04:30PM	2 Biotech Stocks That Could Soar by 130% and 92%, According to Wall Street (Motley Fool)
07:30AM	First Patient Treated in Alpha-1 Antitrypsin Deficiency Liver Disease Phase 3 Study Triggering $40 Million Milestone Payment from Takeda to Arrowhead (Business Wire)
Apr-03-23 07:30AM	Arrowhead Pharmaceuticals Announces $30 Million Milestone Payment from GSK (Business Wire)
Mar-31-23 04:30PM	Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) (Business Wire)
Mar-20-23 07:30AM	Arrowhead Receives FDA Fast Track Designation for ARO-APOC3 (Business Wire)
Mar-06-23 05:28AM	Investing in Arrowhead Pharmaceuticals (NASDAQ:ARWR) five years ago would have delivered you a 329% gain (Simply Wall St.)
Mar-03-23 07:30AM	Arrowhead Pharmaceuticals to Present at 43rd Annual Cowen Health Care Conference (Business Wire)
Feb-28-23 07:30AM	Arrowhead Announces Interim Results from Ongoing Phase 1/2 Study of ARO-C3 for Treatment of Complement Mediated Diseases (Business Wire)
Feb-26-23 08:04AM	12 High Growth Healthcare Stocks to Buy (Insider Monkey)
Feb-15-23 11:29AM	JNJ Terminates NASH Program Pact With Arrowhead Pharmaceuticals (Benzinga)
07:30AM	Arrowhead Pharmaceuticals Gains Full Rights to NASH Candidate ARO-PNPLA3 with Promising Phase 1 Results (Business Wire)
Feb-08-23 02:13PM	Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Q1 2023 Earnings Call Transcript (Insider Monkey)

Arrowhead Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development of medicines that treat intractable diseases by silencing the genes that cause them. The firms preclinical stage drug candidates include ARO-ANG3, ARO-AAT, ARO-APOC3, ARO-HIF2, ARO-HSD, ARO-Lung2, ARO-COV, and ARO-ENaC. The company was founded by Robert Bruce Stewart in 1989 and is headquartered in Pasadena, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Hamilton James C	Chief Discovery/Trans Medicine	Apr 01 '24	Sale	28.03	6,000	168,180	204,851	Apr 03 06:05 PM
Lu Hongbo	Director	Mar 20 '24	Buy	27.50	1,000	27,500	33,680	Mar 20 07:06 PM
Lu Hongbo	Director	Mar 19 '24	Buy	28.00	1,000	28,000	32,680	Mar 20 07:06 PM
Lu Hongbo	Director	Mar 18 '24	Buy	27.49	1,000	27,490	31,680	Mar 20 07:06 PM
Myszkowski Kenneth Allen	Chief Financial Officer	Mar 06 '24	Sale	35.19	40,000	1,407,600	400,600	Mar 08 05:54 PM
Anzalone Christopher Richard	Chief Executive Officer	Jan 31 '24	Option Exercise	14.54	57,499	836,035	3,772,547	Feb 02 05:25 PM
Anzalone Christopher Richard	Chief Executive Officer	Jan 31 '24	Sale	32.35	57,499	1,860,019	3,715,048	Feb 02 05:25 PM
Hamilton James C	Chief Discovery/Trans Medicine	Jan 12 '24	Sale	36.89	7,940	292,904	210,851	Jan 17 06:32 PM
Vakiener Victoria	Director	Jan 11 '24	Sale	38.10	4,720	179,813	32,001	Jan 16 06:06 PM
Waddill William D.	Director	Jan 11 '24	Sale	38.07	3,934	149,759	47,870	Jan 16 06:06 PM
Ferrari Mauro	Director	Jan 11 '24	Sale	38.06	3,147	119,787	60,778	Jan 16 06:06 PM
GIVEN DOUGLAS B	Director	Jan 11 '24	Sale	38.06	2,911	110,788	129,711	Jan 16 06:06 PM
Hamilton James C	Chief Discovery/Trans Medicine	Jan 05 '24	Sale	35.18	32,143	1,130,748	218,791	Jan 05 08:02 PM
O'Brien Patrick	COO and General Counsel	Jan 05 '24	Sale	35.27	22,841	805,716	464,385	Jan 05 07:58 PM
Myszkowski Kenneth Allen	Chief Financial Officer	Jan 05 '24	Sale	35.27	16,104	567,910	440,600	Jan 08 05:16 PM
San Martin Javier	Chief Medical Officer	Jan 05 '24	Sale	35.26	8,303	292,804	198,497	Jan 08 05:16 PM
Oliver Tracie	Chief Commercial Officer	Jan 05 '24	Sale	33.89	74	2,508	136,501	Jan 08 05:17 PM
O'Brien Patrick	COO and General Counsel	Jan 04 '24	Sale	32.63	1,600	52,208	402,226	Jan 05 07:58 PM
O'Brien Patrick	COO and General Counsel	Jan 03 '24	Sale	32.28	8,749	282,439	403,826	Jan 05 07:58 PM
Hamilton James C	Chief Discovery/Trans Medicine	Jan 03 '24	Sale	32.19	6,300	202,781	175,934	Jan 05 08:02 PM
Anzalone Christopher Richard	Chief Executive Officer	Jan 02 '24	Sale	31.01	9,952	308,637	3,715,048	Jan 04 05:25 PM
Anzalone Christopher Richard	Chief Executive Officer	Dec 20 '23	Sale	28.54	12,000	342,480	3,725,000	Dec 22 05:04 PM
San Martin Javier	Chief Medical Officer	Nov 20 '23	Sale	28.80	19,700	567,315	131,800	Nov 22 02:31 PM
Anzalone Christopher Richard	Chief Executive Officer	Oct 25 '23	Sale	24.21	24,338	589,223	3,737,000	Oct 27 06:23 PM
Vakiener Victoria	Director	Sep 28 '23	Sale	26.33	1,550	40,812	21,734	Oct 02 05:51 PM
Anzalone Christopher Richard	Chief Executive Officer	Sep 18 '23	Option Exercise	4.75	57,755	274,336	3,819,093	Sep 20 06:10 PM
Anzalone Christopher Richard	Chief Executive Officer	Sep 18 '23	Sale	28.12	57,755	1,624,223	3,761,338	Sep 20 06:10 PM
Oliver Tracie	Chief Commercial Officer	Jul 03 '23	Sale	35.31	8,925	315,142	61,575	Jul 06 06:04 PM
Hamilton James C	Chief Discovery/Trans Medicine	Jun 30 '23	Sale	35.53	3,000	106,590	188,484	Jul 05 06:15 PM
Myszkowski Kenneth Allen	Chief Financial Officer	Jun 27 '23	Sale	36.20	15,000	543,000	381,704	Jun 29 06:41 PM

affiliate • advertise • toggle light mode • contact • privacy • help
do not sell my data • privacy settings

PTGX

Protagonist Therapeutics Inc

ARWR

Arrowhead Pharmaceuticals Inc.

Upgrade your FINVIZ experience